Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical

SALT LAKE CITY, March 25, 2020 -- (Healthcare Sales & Marketing Network) -- Elevar Therapeutics, Inc., a fast-growing biopharmaceutical company focused on promising therapies for unmet medical needs in cancer, announced today an agreement with Swedish-bas... Biopharmaceuticals, Oncology, Acquisitions Elevar Therapeutics, Oasmia Pharmaceutical, Apealea, paclitaxel
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news